We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine f... Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product. Show more
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
="/Images/box-checked.jpg" alt="Checkbox checked">144: Remarks and SignatureRemarksDate of Notice03/01/2024ATTENTION: The person for whose account the securities to which this notice relates are...
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference PR Newswire EMERYVILLE, Calif., Feb. 27, 2024 EMERYVILLE, Calif., Feb. 27, 2024 /PRNewswire/ -- Dynavax Technologies...
falsefalsefalse--12-310001029142FYhttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent70001029142us-gaap:NonUsMember2021-01-012021-12-31000102914...
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance PR Newswire EMERYVILLE, Calif., Feb. 22, 2024 HEPLISAV-Bยฎย 2023 net product...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.21 | 1.72131147541 | 12.2 | 12.64 | 12.05 | 1063467 | 12.33015464 | CS |
4 | -0.62 | -4.75825019186 | 13.03 | 13.265 | 11.65 | 1938287 | 12.33676015 | CS |
12 | -2.15 | -14.7664835165 | 14.56 | 15.01 | 11.65 | 2032828 | 13.03375523 | CS |
26 | -2.12 | -14.5905024088 | 14.53 | 15.15 | 11.65 | 1795032 | 13.45882497 | CS |
52 | 2.48 | 24.9748237664 | 9.93 | 15.15 | 9.48 | 1664359 | 13.19128355 | CS |
156 | 2.43 | 24.3486973948 | 9.98 | 21.39 | 7.09 | 2191819 | 12.90022613 | CS |
260 | 5.31 | 74.7887323944 | 7.1 | 21.39 | 1.8 | 2606605 | 9.78210294 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions